Bausch + Lomb (BLCO) vs National Vision (EYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bausch + Lomb (BLCO) has outperformed National Vision (EYE) over the past year, gaining 18.3% versus a loss of 39.5%. Bausch + Lomb is the larger company by market cap ($6.19 billion vs $1.33 billion), about 4.7 times the size. On valuation, National Vision trades at a lower forward P/E (13.9x vs 15.6x for Bausch + Lomb).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLCO | EYE |
|---|---|---|
| Share price | $17.34 | $16.82 |
| Market cap | $6.19B | $1.33B |
| 1-day change | +0.93% | +0.48% |
| YTD return | +1.52% | -34.86% |
| 1-year return | +18.28% | -39.50% |
| 5-year return | — | -73.52% |
| P/E ratio (TTM) | — | 27.13 |
| Forward P/E | 15.58 | 13.92 |
| EPS (TTM) | $-0.49 | $0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.10B | — |
| Revenue growth (YoY) | +6.47% | — |
| Net income (latest FY) | $-360.00M | — |
| Operating margin | 2.22% | — |
| Net margin | -7.06% | — |
| 52-week high | $18.92 | $30.02 |
| 52-week low | $13.77 | $14.75 |
| Distance from 52-week high | -8.33% | -43.97% |
| Analyst consensus | buy | none |
| Avg. price target upside | +11.82% | +67.54% |
| Average volume | 392.81K | 2.14M |
| Shares outstanding | 357.17M | 79.07M |
| Employees | 13,000 | 13,138 |
| Sector | Healthcare | Consumer Cyclical |
| Industry | Medical Instruments & Supplies | Specialty Retail |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bausch + Lomb is about 4.7 times larger than National Vision by market value ($6.19B vs $1.33B).
- BLCO has outperformed EYE by 57.8 percentage points over the past year.
- The two companies sit in different sectors: Bausch + Lomb in Healthcare and National Vision in Consumer Cyclical.
About Bausch + Lomb
BLCO stock →Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Healthcare · Medical Instruments & Supplies · 13,000 employees
About National Vision
EYE stock →National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company offers eyeglasses and contact lenses, and optical accessory products; and provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, Vista Optical military, and DiscountContacts.com.
Consumer Cyclical · Specialty Retail · 13,138 employees
BLCO vs EYE FAQ
Which is bigger, Bausch + Lomb or National Vision?
Bausch + Lomb (BLCO) is larger, with a market capitalization of $6.19B compared with $1.33B for National Vision (EYE).
Which stock has performed better over the past year, BLCO or EYE?
BLCO returned +18.28% over the past 12 months, compared with -39.50% for EYE (price return, excluding dividends). Past performance does not predict future results.
Are Bausch + Lomb and National Vision in the same industry?
No. Bausch + Lomb is in the Healthcare sector, while National Vision is in Consumer Cyclical.